Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder ...

Add Yahoo as a preferred source to see more of our stories on Google. A new treatment for advanced bladder cancer which doubles survival time has been approved for NHS use. The treatment for advanced ...

A new treatment for advanced bladder cancer which doubles survival time has been given the green light for NHS use. Experts said the approval of the new treatment combination would bring a ...

The National Institute for Health and Care Excellence (NICE) has recommended the combination of enfortumab vedotin (Padcev, Astellas) with pembrolizumab (Keytruda, MSD) as a first-line option for ...

FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma (PPARG), showed early signs of clinical benefit in patients with advanced ...

Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...